Roadside Medical Clinic to expand reach
KNOXVILLE, Tenn. Roadside Medical Clinic + Lab, which currently has three locations, and Pilot Travel Centers have announced the opening of three new medical clinics, with plans for an additional six locations throughout the United States by the end of the year.
The new medical clinics, which cater to the 4.2 million professional truck drivers on the road nationwide, are located in Oklahoma City, Okla.; East St. Louis, Ill.; and Waco, Texas. Oklahoma City will begin providing health-and-wellness services on June 25, and the Waco and East St. Louis locations will be providing services in July.
All current and new Roadside Medical Clinics use advanced healthcare information systems, including iPads, telemedicine and the industry’s first full-function electronic medical record system for professional drivers.
With its locations on the highways at Pilot Travel Centers, Roadside Medical provides convenient, cost-effective and professional medical care services, including DOT physicals and compliance; wellness programs; sleep apnea screenings, testing and treatment; and nutritional products.
"Our expansion to three additional locations is another step in our development of a coast-to-coast network to support professional drivers where they need us, on the road," stated Bob Perry, president of Roadside Medical Clinic + Lab and chairman for the American Trucking Associations Safety & Loss Prevention Management Council’s Health & Wellness Working Group. "The clinics, in addition to our Driver Body Fuel products and wellness program, provide trucking companies and their drivers with the tools they need to stay on the road to good health."
Merck gets nod from FDA for Dulera
WHITEHOUSE STATION, N.J. The Food and Drug Administration has approved a new drug by Merck for treating asthma in patients ages 12 years and older, Merck said Thursday.
The FDA approved Dulera (mometasone furoate and formoterol fumarate dihydrate), an inhaled, fixed-dose combination asthma treatment.
“Despite the advances made in the treatment of asthma in recent years, many patients may still not be well-controlled on their current therapies,” University of Tennessee Health Science Center medical professor Michael Blaiss said in a statement on behalf of Merck. “Asthma control is an important treatment goal, and Dulera provides a new option for physicians to help manage this chronic condition in appropriate patients.”
FDA approves Mylan’s version of Procardia XL
PITTSBURGH The Food and Drug Administration has approved a generic drug made by Mylan for heart disease, Mylan said Thursday.
Mylan announced the approval of nifedipine extended-release tablets in the 30, 60 and 90 mg strengths. The drug is used to treat hypertension and angina.
The drug is a generic version of Pfizer’s Procardia XL. Branded and generic versions of the drug had sales of around $234 million during the 12-month period ended in March, according to IMS Health.